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| INTRODUCTION
Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at substantial risk of developing invasive fungal infections (IFIs). [1] [2] [3] While major progress in the management of IFIs has been made in recent years following the introduction of newer antifungal agents, IFI-associated morbidity and mortality rates remain high [4] [5] [6] and the economic burden considerable. 7, 8 To reduce the negative impact of IFI-related mortality, morbidity and costs in this patient population, [9] [10] [11] [12] either prophylaxis or early treatment strategies based upon diagnostics-driven approaches using serial biomarkers and systematic imaging may be considered.
Due to their generally good safety profile and convenience in an outpatient setting, oral triazole antifungals (i.e. fluconazole, itraconazole, posaconazole and voriconazole) are frequent choices for antifungal prophylaxis (AFP) in alloHSCT recipients in the posttransplant period. 10, 13, 14 In a national prospective surveillance study of IFIs in HSCT recipients, the incidence of invasive aspergillosis (IA) increased over the observation period, whereas the cumulative incidence of Candida infections remained stable. 4 As a consequence, many centres now use mould-active triazoles for posttransplantation AFP.
While several clinical studies have demonstrated the efficacy of these agents for preventing IFI in this setting, [15] [16] [17] [18] [19] it is currently unknown which is the most cost-effective agent in these patients, especially
as physicians have a choice of both generic and branded antifungal agents.
A review found that AFP in immunocompromised patients with haematological malignancies is likely associated with favourable cost-benefit, cost-effectiveness and cost-saving potential. 2 From this perspective, the newer mould-active triazole antifungals appear to be better alternatives to fluconazole. 2 However, due to the large heterogeneity in the patient population, hospital setting, study methods and underlying disease, together with the shortage of head-to-head studies, the authors were not able to provide clear evidence of an economic advantage for any single prophylactic agent.
In many European countries, voriconazole is approved for the treatment of various types of IFI and IFI-active AFP in alloHSCT.
Intolerance [15] [16] [17] [18] and limitations in absorption 20, 21 of the approved oral azoles have encouraged investigators to examine alternatives for AFP. In order to evaluate the economic impact of voriconazole compared with other oral mould-active azoles (and fluconazole) as primary AFP in the posttransplant period in patients undergoing alloHSCT, we developed a decision-analytic economic model and conducted a costeffectiveness analysis (CEA) of voriconazole.
| MATERIALS AND METHODS

| Model structure
To determine the costs and outcomes associated with AFP, a decisionanalytic model ( Cost-effectiveness analysis decision-analytic model structure. The model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT, and took the perspective of the Spanish National Health System. It was assumed that antifungal prophylaxis started at the time of transplant (day 0) and that all impacts of IFI would occur in the short-term, defined as within 180 days of transplant. *OLAT was permitted either as alternative AFP or for preemptive/empirical therapy of suspected IFI. However, for simplicity, OLAT is not depicted in the figure since probabilities of IFI and death were not stratified based on OLAT use. Rather, each comparator is assigned a cost representing use of OLAT. AFP, antifungal prophylaxis; alloHSCT, allogeneic haematopoietic cell transplantation; IFI, invasive fungal infection; OLAT, other licensed antifungal treatment comparator were based on published clinical trial data and confirmed by expert opinion comprising a panel of co-authors from Spain (CS, IJ and CG-V, chaired by EJB).
The model assumed that all patients assigned to prophylaxis with an oral azole either did or did not develop a proven/probable break- 
| Clinical inputs
Key clinical inputs are summarised in Table 1 . 14, 15, 18, [22] [23] [24] [25] [26] For each prophylactic regimen, the probability of developing proven/probable breakthrough IFI and the proportion of patients requiring OLAT were derived from a mixed treatment comparison (MTC) 14 of relevant RCTs.
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For each prophylactic agent, the specific type and distribution of alternative antifungal agents given as OLAT was based on clinical expert opinion. For voriconazole, the distribution of alternative antifungal agents given as OLAT was as follows: intravenous (iv) caspofungin (30%), iv liposomal amphotericin B (60%) and oral posaconazole (10%); for itraconazole, the distribution of alternative antifungal agents given as OLAT was: iv caspofungin (30%), iv liposomal amphotericin B (30%), iv voriconazole (30%) and oral posaconazole (10%); and for both fluconazole and posaconazole, the distribution of alternative antifungal agents given as OLAT was assumed to be the same as for voriconazole: iv caspofungin (30%), iv liposomal amphotericin B (60%) and oral posaconazole (10%). Posaconazole as OLAT would be given at treatment dose, that is, 800 mg daily in two to four divided doses.
The duration of prophylaxis was derived primarily from the pub- Marks et al. [15] given that, in this CEA, antifungal prophylaxis started at the time of transplant, rather than at the time of graft-versus-host Data presented are based on the cited source material and clinical expert opinion. b Duration of prophylaxis for POS is assumed to be the same as the duration of prophylaxis for VOR. c Cost of treating "other IFI" is assumed to be the same as cost of treating IA. d Non-IFI mortality at 180 days was derived from an observational cohort study conducted in Spain 26 in which global mortality 2 years after transplantation was 32% (16/50). Death was infection related in 12% (6/50) and there were 10/50 (20%) "other" (non-infection) deaths after 2 years. All-cause mortality at Day 100 was cumulative (11/50, 22%). Because of the low observed incidence of IFI (3/50), which the investigators attributed to universal AFP with fluconazole and low Aspergillus spp., most of the mortality was non-IFI. In our model, these estimates were reviewed with the clinicians and 20% was regarded as a good approximation for Day 180. To account for uncertainty, this rate was varied in a sensitivity analysis and applied to each comparator.
disease (GvHD) as in the posaconazole RCT. 17 Furthermore, other studies in alloHSCT patients have confirmed the tolerability of posaconazole compared with fluconazole 27 or posaconazole-micafungin bridging 13 in the early posttransplant period, thus supporting the extrapolation of Ullmann et al. [17] study results to alloHSCT from Day 0.
Mortality rates were derived from the published literature. In the absence of relevant Spanish data, IFI-related mortality rates were derived from a retrospective cohort study of 98 alloHSCT patients that reported attributable mortality rates for Italy. 25 Non-IFI mortality at 180 days was derived from an observational cohort study of 50 alloHSCT patients that reported mortality associated with alloHSCT at 2 years posttransplant in Spain.
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| Cost inputs
Key cost inputs are summarised in Table 1 another CEA evaluating prophylactic treatments for IFI following alloHSCT in Spain, 24, 28 whereas the cost of treating candidaemia/IC was based on a cost study of patients hospitalised with IC in Spain. 23 The cost of treating other IFI was assumed to be the same as for IA. 
| Determination of cost-effectiveness
An incremental cost-effectiveness ratio (ICER) was used to measure cost-effectiveness. The ICER measures the additional cost necessary to achieve an improved clinical outcome when comparing a treatment with the next least effective agent. The ICER in this model was specifically calculated as the ratio of the difference in costs to the difference in clinical outcomes, such as IFI avoided with one AFP agent compared with the next best alternative AFP agent. The resulting ICER was a numerical value if an AFP agent provided additional improved clinical outcomes at an increased cost. However, if an AFP agent was expected to provide fewer health benefits at an increased cost, the ICER was not calculated, and the drug was considered "dominated" by the next best alternative AFP agent.
| Sensitivity analysis
| One-way sensitivity analysis
To understand the impact of each model parameter on the model results, a one-way sensitivity analysis was conducted in which each model parameter was independently varied. An additional analysis comparing posaconazole oral suspension and voriconazole was conducted because these two agents are currently not available in generic form in Spain, but are frequently used for the prevention of invasive mould infections in high-risk alloHSCT patients. Individual parameters used in the base-case scenario were replaced with estimated low (minimum) and high (maximum) values for sensitivity analysis.
| Probabilistic sensitivity analysis (PSA)
A PSA involving 1000 model replications was used to measure the overall uncertainty associated with model results (as a function of uncertainty about each parameter at the same time). The PSA evaluated the impact of this uncertainty on the estimated cost-effectiveness of the comparator agents involved.
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| RESULTS
| Base-case scenario
Costs and outcomes based on the hypothetical cohort of 1000 patients are summarised in Table 2 
| Sensitivity analysis
| One-way sensitivity analysis
In a comparison of voriconazole and itraconazole, the incremental cost per IFI avoided was most sensitive to probability of IFI, drug cost of voriconazole and duration of prophylaxis of voriconazole (Fig. 2) . In a comparison of posaconazole oral suspension with voriconazole, the incremental cost per IFI avoided was also most sensitive to probability of IFI and drug cost of posaconazole and voriconazole.
| Probabilistic sensitivity analysis
Results of the PSA (Fig. 3) (Fig. 4) . Figure 4 shows the probability of each comparator being cost-effective given a specific willingness to pay (WTP) threshold.
At lower WTP thresholds, itraconazole had the highest probability of being cost-effective in terms of IFI avoided compared with all other treatments in the cost-effectiveness comparison. While fluconazole and itraconazole both have a high probability of being cost-effective relative to voriconazole at lower WTP thresholds, even at large WTP thresholds, voriconazole was consistently more likely to be cost-effective relative to posaconazole oral suspension in terms of IFI avoided.
| DISCUSSION
There is currently no widely accepted standard agent for posttransplantation AFP in patients undergoing alloHSCT. 30 Fluconazole has been used for AFP before and after transplantation. 10 the rising number of patients undergoing high-risk alloHSCT, together with an increase in the frequency of IA and other systemic mould infections, has encouraged many transplant centres to use a mouldactive antifungal agent for prophylaxis in the posttransplantation setting. 25, [33] [34] [35] Given that the economic impact of IFI is significant, The results of a previously presented MTC provided the basis for the present analyses. 14 This MTC showed that, among the mouldactive azoles, posaconazole and voriconazole appeared to reduce the risk of IA more than itraconazole; in contrast, itraconazole was most effective in preventing IC, a finding that is consistent with previously published meta-analyses. 37, 38 However, these differences
were not statistically significant, and the authors suggested that other WTP thresholds, many patients experience tolerability issues, which may limit its use as a prophylactic agent. 15 As such, we were also interested in the comparison between posaconazole and voriconazole. In this setting, voriconazole resulted in greater cost savings and superior efficacy in the base-case analysis.
Results of the PSA indicate that there is still some uncertainty surrounding the efficacy differences between comparator treatments; however, there are clear cost differences between the three comparator drugs and itraconazole, which may account for the predicted differences in cost-effectiveness.
In another decision-analytic model using the perspective of the Spanish National Health Service, and similar to the one described in this report, the incidence of breakthrough IFI with posaconazole was reported as 5.3% compared with 9% for fluconazole. This difference may be due to the small variations in the effectiveness of both drugs. In addition, and again similar to the findings presented here, Mauskopf et al. [40] demonstrated that fluconazole is cost-effective compared with voriconazole in 599 HCT recipients over 6 months. However, in a sub analysis of patients with acute myeloid leukaemia, the investigators showed that the cost per IFI avoided was lower among patients who received voriconazole relative to the full study population over both 6 and 12 months.
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Although we did not look at acute myeloid leukaemia patients in this study nor conduct the analysis over a 12-month period, this is an important area for future research. When comparing different CEAs, it should be considered that the inputs and results of any CEA are specific to the country and perspective under investigation, and may not be generalisable to other settings.
| Study strengths and limitations
A pharmacoeconomic model is a powerful tool that can combine data for multiple variables (IFI, OLAT, prophylaxis duration) to estimate the ultimate cost and clinical outcomes for a hypothetical cohort.
Unlike previous analyses, this is the first pharmacoeconomic model to use data from multiple RCTs. It is also the first pharmacoeconomic model to compare all the available azoles, and the first to compare both posaconazole oral suspension and voriconazole. However, one limitation is that the CEA relied on data derived from a previous MTC analysis. 14 Although MTCs are increasingly used in healthcare to overcome the limitations of the evidence network by borrowing weight from indirect comparisons of available drugs, the MTC approach is also limited by the data inputs and any assumptions used F I G U R E 4 Cost-effectiveness acceptability curves for an additional IFI avoided. Relationship between the probability of each comparator being cost-effective and willingness to pay for an additional IFI avoided. IFI, invasive fungal infection to inform the analysis. A CEA is not a substitute for a randomised clinical trial directly comparing available treatments. However, in the absence of such a trial, the pharmacoeconomic analyses conducted for this study provide useful information that can assist in medical decision-making. The CEA did not explicitly consider GvHD and neutropenia, since the relevant randomised clinical trials (RCTs) [15] [16] [17] [18] [19] used to inform the model did not report sufficiently detailed data regarding these events in a homogeneous population (e.g. probability such as long-term tolerability, local IFI epidemiology, drug-to-drug interactions, pharmacokinetic differences and the option to switch to an iv formulation (in case of oral absorption issues), should be considered.
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